Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development
Recruiting
N/A
Interventional Study
Atrial Fibrillation (AF)
Premature Atrial Complexes
Atrial Arrhythmias
Artificial Intelligence (AI)
Electrocardiogram
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 40 Days – 85 Days
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 14,726 (estimated)
- Sponsor
- National Defense Medical Center, Taiwan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs \> 20 beats, non-sustained AF/AFL.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients in the inpatient department or the outpatient department
* Patients need to have at least one electrocardiogram within one year
Exclusion Criteria:
* Diagnosis of atrial fibrillation/atrial flutter
* History of atrial fibrillation/atrial flutter catheter ablation
* …
Contacts